AI Article Synopsis
Article Abstract
Since twenty years, many nanoparticles based on high atomic number elements have been developed as radiosensitizers. The design of these nanoparticles is limited by the classical rules associated with the development of nanoparticles for oncology and by the specific ones associated to radiosensitizers, which aim to increase the effect of the dose in the tumor area and to spare the health tissues. For this application, systemic administration of nanodrugs is possible. This paper will discuss the development of AGuIX nanoparticles and will emphasize on this example the critical points for the development of a nanodrug for this application. AGuIX nanoparticles display hydrodynamic diameters of a few nanometers and are composed of polysiloxane and gadolinium chelates. This particle has been used in many preclinical studies and is evaluated for a further phase I clinical trial. Finally, in addition to its high radiosensitizing potential, AGuIX display MRI functionality and can be used as theranostic nanodrug for personalized medicine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canrad.2015.05.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical Photodynamic Therapy Targeting Blood Vessels with AGuIX Theranostic Nanoparticles.
Cancers (Basel)
November 2024
Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 7 Gronostajowa Street, 31-387 Krakow, Poland.
Glioblastoma multiforme (GBM) is the most common highly aggressive, primary malignant brain tumor in adults. Current experimental strategies include photodynamic therapy (PDT) and new drug delivery technologies such as nanoparticles, which could play a key role in the treatment, diagnosis, and imaging of brain tumors. The purpose of this study was to test the efficacy of PDT using AGuIX-TPP, a polysiloxane-based nanoparticle (AGuIX) that contains TPP (5,10,15,20-tetraphenyl-21H,23H-porphine), in biological models of glioblastoma multiforme and to investigate the vascular mechanisms of action at multiple complexity levels.
View Article and Find Full Text PDFUse of nanoparticles in radiation oncology.
Cancer Radiother
November 2024
Radiotherapy Department, Grenoble Alps University Hospital, Grenoble, France; Inserm UA7, University of Grenoble Alps, Synchrotron Radiation for Biomedical Research (ESRF), Grenoble, France.
Article Synopsis
- Radiotherapy plays a crucial role in treating cancer but often struggles with effective local control, especially in advanced tumours that are resistant to radiation.
- Surrounding healthy tissues often limit how much radiation can be safely used, which can lead to complications.
- New agents like chemotherapies and targeted monoclonal antibodies have shown promise in improving treatment outcomes, and current research is exploring innovative radioenhancers, particularly nanoparticles like NBTXR3 and AGuIX®.
Energy Transfer between AGuIX Nanoparticles and Photofrin under Light or X-ray Excitation for PDT Applications.
Pharmaceuticals (Basel)
August 2024
Université de Lorraine, CNRS, LRGP, 54600 Nancy, France.
Photodynamic therapy is an accepted therapy cancer treatment. Its advantages encourage researchers to delve deeper. The use of nanoparticles in PDT has several advantages including the passive targeting of cancer cells.
View Article and Find Full Text PDFBackground: In glioblastoma (GBM), tumor progression occurs mainly within the irradiated tumor volume. To address this challenge, a radiosensitization strategy with intravenous gadolinium-based theranostic nanoparticles (AGuIX) is being explored in the NANO-GBM phase1b/2R trial (NCT04881032). Here, we present the results of the phase 1b part, which is the first-in-human use of these nanoparticles with radiotherapy and chemotherapy for the treatment of newly diagnosed GBM.
View Article and Find Full Text PDFTheragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer.
ACS Nano
July 2024
Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94805, France.
Article Synopsis
- AGuIX nanoparticles are gadolinium-based agents that serve as both MRI contrast agents and enhance the effectiveness of X-ray radiation therapy for cancer treatment.
- A phase I trial tested the safety and optimal dosage of AGuIX in combination with conventional therapies for 12 patients with advanced cervical cancer, showing good tolerability and no severe side effects.
- The treatment resulted in complete remission of the primary tumors in all but one patient, highlighting the potential of these nanoparticles to improve the precision of tumor targeting and enhance radiotherapy outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!